Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMD NASDAQ:LRMR NASDAQ:MDWD NASDAQ:PDSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$4.02-3.6%$3.95$3.04▼$8.10$228.14M1.21167,046 shs88,157 shsLRMRLarimar Therapeutics$3.21-3.3%$2.66$1.61▼$9.97$212.57M0.86842,629 shs480,386 shsMDWDMediWound$20.46+2.0%$20.19$14.14▼$22.51$216.70M0.3264,521 shs77,898 shsPDSBPDS Biotechnology$1.15-4.2%$1.45$0.85▼$4.32$54.85M1.21476,197 shs289,150 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote-3.60%-1.47%+0.75%+21.82%-51.27%LRMRLarimar Therapeutics-3.31%-5.03%+17.15%+68.50%-68.19%MDWDMediWound+2.04%+2.15%+5.30%+19.65%+0.64%PDSBPDS Biotechnology-4.17%-7.26%-28.57%+6.48%-71.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTMDbiote2.6487 of 5 stars3.52.00.00.00.03.31.3LRMRLarimar Therapeutics2.2534 of 5 stars3.62.00.00.02.81.70.0MDWDMediWound1.3229 of 5 stars3.51.00.00.00.00.80.6PDSBPDS Biotechnology1.1656 of 5 stars3.71.00.00.01.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 3.00Buy$8.0099.00% UpsideLRMRLarimar Therapeutics 3.11Buy$18.50476.32% UpsideMDWDMediWound 3.00Buy$32.2557.62% UpsidePDSBPDS Biotechnology 3.33Buy$9.00682.61% UpsideCurrent Analyst Ratings BreakdownLatest PDSB, MDWD, BTMD, and LRMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/24/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/24/2025LRMRLarimar TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.006/24/2025LRMRLarimar TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.006/11/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/2/2025MDWDMediWoundOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$34.005/22/2025MDWDMediWoundHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.00 ➝ $31.005/2/2025MDWDMediWoundAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$197.19M1.12$0.74 per share5.44($2.78) per share-1.45LRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/AMDWDMediWound$20.22M10.94N/AN/A$2.89 per share7.08PDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$3.16M$0.616.597.44N/A10.93%-19.44%20.12%8/6/2025 (Estimated)LRMRLarimar Therapeutics-$80.60M-$1.49N/AN/AN/AN/A-52.48%-46.08%8/6/2025 (Estimated)MDWDMediWound-$30.22M-$2.09N/AN/AN/A-110.45%-74.12%-30.92%8/13/2025 (Estimated)PDSBPDS Biotechnology-$37.61M-$0.94N/AN/AN/AN/A-150.59%-69.15%8/12/2025 (Estimated)Latest PDSB, MDWD, BTMD, and LRMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BTMDbiote$0.06N/AN/AN/A$49.52 millionN/A8/13/2025Q2 2025MDWDMediWound-$0.55N/AN/AN/A$5.68 millionN/A8/12/2025Q2 2025PDSBPDS Biotechnology-$0.24N/AN/AN/AN/AN/A8/6/2025Q2 2025LRMRLarimar Therapeutics-$0.4877N/AN/AN/AN/AN/A5/21/2025Q1 2025MDWDMediWound-$0.65-$0.07+$0.58-$0.07$5.20 million$3.96 million5/14/2025Q1 2025PDSBPDS Biotechnology-$0.25-$0.21+$0.04-$0.21N/AN/A5/7/2025Q1 2025BTMDbiote$0.06$0.08+$0.02$0.37$47.25 million$48.99 million4/30/2025Q1 2025LRMRLarimar Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A1.421.14LRMRLarimar TherapeuticsN/A7.487.48MDWDMediWoundN/A2.151.99PDSBPDS Biotechnology0.292.332.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%LRMRLarimar Therapeutics91.92%MDWDMediWound46.83%PDSBPDS Biotechnology26.84%Insider OwnershipCompanyInsider OwnershipBTMDbiote24.00%LRMRLarimar Therapeutics4.50%MDWDMediWound9.20%PDSBPDS Biotechnology9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19454.71 million41.58 millionNot OptionableLRMRLarimar Therapeutics3064.03 million61.15 millionOptionableMDWDMediWound8010.81 million9.81 millionOptionablePDSBPDS Biotechnology2045.71 million41.51 millionOptionablePDSB, MDWD, BTMD, and LRMR HeadlinesRecent News About These CompaniesPDS wasn’t a bad deal, few greedy individuals cannibalised it with self-serving interests – John JinaporJuly 16 at 11:29 PM | modernghana.comMPDS deal was not bad but greedy people decided to cannibalise the process - JinaporJuly 16 at 11:29 PM | ghanaweb.comGEnergy Minister blames ‘greedy individuals’ for undermining ‘otherwise good’ PDS dealJuly 16 at 6:28 PM | myjoyonline.comMPDS to pay final dividend of ₹1.70, ex-date due tomorrow; last day today to trade sharesJuly 16 at 5:14 AM | moneycontrol.comThe top headlines for PDS Health’s busy 2025 so farJuly 12, 2025 | beckersdental.comBPDS Biotechnology stock rises after trial meets criteria for expansionJuly 10, 2025 | investing.comPDS Biotechnology Shares Climb Following Trial Expansion MilestoneJuly 10, 2025 | msn.comPDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 ResultsJuly 10, 2025 | globenewswire.comASIC consults on simplifying PDS guidanceJuly 10, 2025 | professionalplanner.com.auPAP: over 11k kg of PDS rice seized in a private premiseJuly 10, 2025 | uniindia.comUOne arrested for smuggling PDS rice near TiruchiJuly 7, 2025 | thehindu.comPDS Health adds practices in 5 statesJuly 3, 2025 | beckersdental.comB3 booked for illegally transporting PDS food grains stock for sale in ThaneJuly 3, 2025 | theprint.inTPDS arm inks pact to acquire 60% stake in GSC LinkJuly 3, 2025 | business-standard.comBPDS Biotechnology (NASDAQ:PDSB) Given "Buy" Rating at HC WainwrightJuly 1, 2025 | marketbeat.comTwo errant traders arrested; 79.3 quintals of PDS rice seizedJune 25, 2025 | thehindu.comPDS Health Raises Over $1.9 Million Through Smile Generation to Support charity: water's Clean Water ProjectsJune 25, 2025 | kxan.comKPDS Biotechnology Corporation (PDSB) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comPDS Health ranked among most community-minded companiesJune 13, 2025 | beckersdental.comBUnpacking the PDS PhenomenonJune 11, 2025 | devdiscourse.comDPDS rice will be distributed till June 30: Civil Supplies deptJune 11, 2025 | thehansindia.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimePDSB, MDWD, BTMD, and LRMR Company Descriptionsbiote NASDAQ:BTMD$4.02 -0.15 (-3.60%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$4.02 0.00 (0.00%) As of 07/18/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Larimar Therapeutics NASDAQ:LRMR$3.21 -0.11 (-3.31%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.22 +0.01 (+0.31%) As of 07/18/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.MediWound NASDAQ:MDWD$20.46 +0.41 (+2.04%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$20.45 -0.01 (-0.05%) As of 07/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.PDS Biotechnology NASDAQ:PDSB$1.15 -0.05 (-4.17%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.14 0.00 (-0.43%) As of 07/18/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
